In partnership with Genesis Analytics, Euro Health Group has been contracted by Unitaid to conduct a joint end of project evaluation for the “Enabling scale-up of Pre-Exposure Prophylaxis (PrEP) and Linkage to HIV Testing (launched in 2015)”, comprising two grants: Preparedness for the rollout of effective HIV prevention among key affected populations in Brazil, Mexico and Peru; and Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women in South Africa.
ImPrEP is the first transnational project, including several studies, in Latin America aiming to generate evidence on the feasibility, acceptability and cost-effectiveness of PrEP among key populations (men who have sex with men and transgender people including trans gender women) specific to the cultural contexts and health systems in Brazil, Mexico and Peru. ImPrEP’s results could allow stakeholders to evaluate and incorporate PrEP as part of combination HIV prevention in their countries.
Focused on OR Tambo District (Eastern Cape), Nelson Mandela District (Eastern Cape) and eThekwini Districts (KwaZulu-Natal), the PrEP project aims to reach 6,640 Adolescent Girls and Young Women aged between 15 and 24 years by building the capacity of National Department of Health, creating demand and mobilising communities to facilitate large scale access to, and uptake of, PrEP, supporting PrEP supply and conducting ongoing routine monitoring and evaluation data collection and research.
With both projects coming to an end in 2020, Unitaid commissioned this end-of-project evaluation to assesses the relevance, coherence, efficiency, effectiveness, impact and sustainability under this area of intervention. Importantly, the evaluation will also target unpacking and identifying lessons learned to potentially inform the roll-out of expanded PrEP technologies, e.g., long-acting injectable cabotegravir.